Key result
Type D personality was associated with an increased risk of non-response to an 8-week trial of fluoxetine in depressed and/or anxious adolescents.
Why the study?
Do psychological (Type D personality) and biological (TNFα, IL-6, IL-1b) markers predict treatment response to fluoxetine in depressed and/or anxious adolescents?
Observational (n=41)
Open-label
Do psychological (Type D personality) and biological (TNFα, IL-6, IL-1b) markers predict treatment response to fluoxetine in depressed and/or anxious adolescents?
Type D personality and initial TNFα levels may serve as predictors of non-response to fluoxetine in adolescents with severe affective or anxiety disorders.
Answers are grounded in this paper and cite their sources.
Should not yet change fluoxetine prescribing in adolescents; hypothesis-generating association requires prospective confirmation.
BACKGROUND: Not enough is known about predicting therapeutic response to serotonin-specific reuptake inhibitors, and specifically to fluoxetine. This exploratory study used psychological and biological markers for (retrospective) prediction of treatment-response to fluoxetine in depressed and/or anxious adolescents. METHODS: Forty-one consecutive adolescent outpatients with a primary diagnosis of severe affective and/or anxiety disorders were assessed and treated with an open-label 8-week trial of fluoxetine. Type D personality was assessed with the 14-item questionnaire, the DS14. In addition, TNFα, IL-6, and IL-1b were measured pre- and post-treatment. RESULTS: There was an elevation of Type D personality in patients, compared to the adolescent population rate. Post-treatment, 44% of patients were classified as non-responders; the relative risk of non-response for Type D personality patients was 2.8. Binary logistic regression predicting response vs. non-response showed a contribution of initial TNFα levels as well as Type D personality to non-response. CONCLUSIONS: In this exploratory study, the most significant contributor to non-response was Type D personality. However, the measurement of Type D was not prospective, and thus may be confounded with psychiatric morbidity. The measurement of personality in psychiatric settings may contribute to the understanding of treatment response and have clinical utility.
No takes yet. Share an insight, caveat, or question.
Zohar et al. (2018) conducted an observational in severe affective and/or anxiety disorders (n=41). Type D personality vs. non-Type D personality was evaluated on non-response to fluoxetine (RR 2.8). Type D personality was associated with an increased risk of non-response to an 8-week trial of fluoxetine in depressed and/or anxious adolescents.
Synapse has enriched 10 related papers. Consider them for comparative context: